Baird raised the firm’s price target on Ambrx Biopharma to $12 from $11 and keeps an Outperform rating on the shares. The analyst believes shares could trade incrementally higher after AACR, with the poster on the phase 1 clinical trial of anti-PSMA ADC ARX517 for prostate cancer bringing attention to this underappreciated agent.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMAM:
- Largest borrow rate increases among liquid names
- Oppenheimer emerging biotech analyst to hold analyst/industry conference call
- Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
- Ambrx Biopharma call volume above normal and directionally bullish
- Ambrx Biopharma falls -26.7%
